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Abstract
Background: Individuals who carry deleterious BRCA mutations face significantly elevated risks of breast, ovarian,
and other cancers. These individuals are also responsible for informing relatives of their increased risk for carrying
the family BRCA mutation. Few interventions have been developed to facilitate this family communication process.
Methods: We developed the Sharing Risk Information Tool (ShaRIT), a personalized educational intervention, to
support BRCA carriers as they discuss BRCA positive results and their implications with relatives. We conducted a
pilot study of 19 BRCA carriers identified through the University of California San Francisco Cancer Risk Program.
Our study had two aims: 1) to assess the feasibility and acceptability of ShaRIT, and 2) describe characteristics
associated with increased family communication and BRCA testing. Participants in our study were divided into two
groups: those who had not received ShaRIT as part of their genetic counseling protocol (control group, n = 10)
and those who received ShaRIT (n = 9).
Results: All 9 women who received ShaRIT reported that it was a useful resource. Characteristics associated with
increased sharing and testing included: female gender, degree of relationship, and frequency of communication.
Increased pedigree knowledge showed a trend toward higher rates of sharing.
Conclusions: Both participants and genetic counselors considered ShaRIT a well-received, comprehensive tool for
disseminating individual risk information and clinical care guidelines to Hereditary Breast and Ovarian Cancer
Syndrome families. Because of this, ShaRIT has been incorporated as standard of care at our institution. In the
future we hope to evaluate the effects of ShaRIT on family communication and family testing in larger populations
of BRCA positive families.
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Background
BRCA testing for women at high risk of Hereditary
Breast and Ovarian Cancer (HBOC) Syndrome is
recommended by multiple professional associations
[1-3]. For women who test positive for a deleterious
BRCA1 or BRCA2 mutation, the lifetime risk of breast
cancer is up to 85% and the lifetime risk of ovarian can-
cer is up to 60% [4,5]. First-degree relatives of a BRCA
carrier have a 1 in 2 chance of carrying the known
family mutation, and second-degree relatives have a 1 in
4 chance.
One of the most clinically important ways to poten-
tially decrease cancer incidence in HBOC is to target
genetic testing towards families with known deleterious
mutations. BRCA testing for a known family mutation
costs a fraction of the price of full sequence BRCA test-
ing, making it an extremely cost-effective way to identify
at-risk BRCA carriers [6]. In HBOC families, knowledge
of a relative’s BRCA status is important to individualize
recommendations for risk-reduction and screening [7].
Privacy laws preclude health care professionals from
initiating contact with relatives, often leaving the “duty
to warn” with the index carrier (the individual first
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reasons, it is becoming increasingly important for BRCA
carriers, and particularly for index carriers, to communi-
cate genetic information with relatives.
Prior studies have examined sharing of BRCA results
with at-risk relatives and their uptake of BRCA testing,
as well as predictors of sharing and testing. Rates of
sharing BRCA positive results with first and second-
degree at-risk relatives in prior studies are quite high,
ranging from 59%-86% [9-12]. BRCA carriers are more
likely to share their results with female relatives and
first-degree relatives, while infrequent contact and emo-
tionally distant relationships have been identified as bar-
riers to communication [10,13]. Despite high rates of
communication, the uptake of genetic testing by at-risk
family members remains significantly lower. Prior stu-
dies have found that as little as 36% of first- and sec-
ond-degree relatives pursue BRCA testing, even if it is
provided free of charge [9,14,15]. Data from our institu-
tion suggests that an index carrier’sk n o w l e d g eo fh e r -
editary breast and ovarian cancer, as well as her
satisfaction with the decision to BRCA test are asso-
ciated with her relatives’ decision to undergo genetic
testing [14].
When BRCA carriers inform relatives of their own
results, they often also share information about their
relative’s risk of carrying a deleterious BRCA mutation.
This risk communication process can be difficult, and
important health information may be subject to non-
communication, mis-communication, or mis-interpreta-
tion. Although BRCA carriers are educated about
HBOC during genetic counseling and risk assessment,
some studies show that several domains of knowledge
remain low after genetic counseling, including under-
standing of gene transmission, risk probabilities among
relatives, and how BRCA results can inform surveillance
recommendations for relatives [15]. We hypothesize that
a personalized educational program that supplements
genetic counseling and focuses on sharing risk informa-
tion with relatives is potentially an efficient and inex-
pensive way of increasing downstream genetic testing in
at-risk relatives.
Few interventions to increase rates of genetic testing
uptake in at-risk relatives have been developed [16].
Recent literature has calledf o ram o r et a i l o r e de d u c a -
tion of patients to improve family communication and
testing [14]. The index BRCA tester is key to beginning
this communication process. A recent review concluded
with an appeal for the “development of an intervention
to directly support people in talking to their relatives”
[17]. One European study warned that communication
can be a “children’s whisper game, where many errors
can occur in the transmission of DNA-test result infor-
mation in families” [18]. It is therefore important to
provide these index carriers with the appropriate tools
to accurately communicate with family members regard-
ing their potential risk of carrying a mutation.
To address these calls for an intervention and to study
the process of sharing BRCA results with relatives, we
developed a pilot program termed ShaRIT (Sharing Risk
Information Tool). ShaRIT is a personalized informa-
tional tool that provides index patients with educational
r e s o u r c e sa n ds u p p o r tm e c h a n i s m s ,a sw e l la sp e r s o n a l
risk assessment information for every at-risk first and
second degree relative. ShaRIT strives to ease the “bur-
den of the messenger” [19] and decrease the possibility
of mis-communicating and mis-interpreting important
medical information to their relatives [10,13,20-23].
This pilot study of the novel informational program
ShaRIT aims to:
1. Test the acceptability and feasibility of ShaRIT from
the perspectives of study participants and their genetic
counselors.
2. Examine rates of sharing BRCA results and family
testing in relatives, as well as predictors of increased
sharing and testing, to inform future, larger studies.
Methods
Population
Recruitment
We recruited participants from the University of Califor-
nia San Francisco (UCSF) Cancer Risk Program, which
provides genetic counseling and BRCA testing at the
UCSF Helen Diller Family Comprehensive Cancer
Center.
All women who received genetic counseling and tested
positive for a germline BRCA1 or BRCA2 mutation at
the Helen Diller Family Comprehensive Cancer Center
between August 2009 and June 2010 were eligible for
this study. Women who enrolled in the Institutional
Review Board-approved UCSF Cancer Risk Program fol-
low-up protocol [24] were contacted by phone or email
in August and September 2010.
Eligibility criteria
Patients were excluded from participation if they met
any of the following exclusion criteria: 1) had plans to
move outside the United States within six months, 2)
did not speak English at a 6
th grade level, 3) had any
cognitive impairment (e.g. dementia), or 4) had a life
expectancy of less than 12 months.
Inclusion criteria for relatives in the sharing and test-
ing analyses were based on strict eligibility criteria
designed by physician experts and genetic counselors
through guidelines from the National Comprehensive
Cancer Network [3] and genetic counseling guidelines
set by the National Society of Genetic Counselors [2].
Relatives eligible for communication of BRCA positive
results (sharing results) met the following criteria: no
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months, age ≥ 16 years old, 50% chance of carrying a
mutation if a first-degree relative, and a 25% chance of
carrying a mutation if a second-degree relative or cou-
sin. To be eligible for testing for a known family muta-
tion, relatives had to meet inclusion criteria for sharing
and be at least 25 years old (the youngest age at which
cancer screening is recommended if the relative tests
positive). A panel of physician experts and genetic coun-
selors convened to determine which relatives were eligi-
ble for sharing results and for family testing (based on
age, medical history, and mutation risk).
Figures 1 and 2 show family pedigrees of two ShaRIT
participants to illustrate how study inclusion criteria
were applied to relatives for sharing results and for
family testing.
Control group
Before ShaRIT was introduced at the UCSF Cancer Risk
Program, the following standard of care was practiced at
the in-person genetic counseling visit to disclose BRCA
results. After verbally informing patients of their BRCA
positive status, they are given a single page lab report of
their BRCA results. At this in-person visit, the implica-
tions of these results are discussed as they relate to the
patient and to the patient’s relatives. A longer persona-
lized medical report (typically 3-4 pages) is sent to the
patient by mail that describes and reviews the genetic
testing process and the implications of the patient’s
BRCA test results. BRCA carriers are therefore informed
in person and by mail of the importance of sharing
genetic test results with family members. A single page
“family letter” is provided to patients who express an
interest in receiving help with communicating their
BRCA results to relatives.
Patients who participated in the control group of this
study tested positive between August 1, 2009 and Febru-
ary 1, 2010, signed an IRB-approved informed consent,
and participated in the study phone survey.
ShaRIT group
The Sharing Risk Information Tool (ShaRIT), described
in detail below, was incorporated into clinical practice at
the UCSF Cancer Risk Program in February 2010.
Patients who tested positive between February 1, 2010
and June 30, 2010, signed an IRB-approved informed
consent, and participated in the study phone survey
were included in the intervention, or ShaRIT group.
Table 1 describes the resources provided to partici-
pants in both the control and the ShaRIT groups as part
of the BRCA results disclosure process.
Sharing risk information tool (ShaRIT)
ShaRIT is an educational tool of genetic information
and family resources organized in a binder given to
BRCA carriers during the in-person results disclosure
visit with a genetic counselor. Each ShaRIT binder
includes:
- The patient’s personalized medical report, which is
typically 3-4 pages
- Family pedigree
- BRCA mutation report from Myriad Genetics
- Personalized recommendations for surveillance and
prevention
Figure 1 Family pedigree of ShaRIT participant illustrating
relative inclusion criteria. The pedigree of the participant (arrow)
shows a strong maternal family history of breast and ovarian cancer.
Genetic counseling recommendations encourage testing of eligible
relatives on the patient’s maternal side. Stars denote the
participant’s mother, maternal aunt, and two maternal cousins, who
are all eligible for sharing results and for family testing. The
participant’s daughter and son are too young to be included in
sharing results or family testing analyses, as they are 13 and 9 years
old.
Figure 2 Family pedigree of ShaRIT participant illustrating
relative inclusion criteria. The pedigree of the participant (arrow),
who tested positive, does not show a strong family history of HBOC
on either the maternal or paternal side. The participant’s mother
tested negative for the known family mutation, so it was likely
inherited from the participant’s father. The participant’s brother, two
sisters (first-degree relatives), and paternal uncles represent first and
second-degree relatives eligible for sharing results and family testing
(stars). The participant’s two daughters are too young to be
included in sharing results or family testing analyses, as they are 7
and 5 years old.
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BRCA mutation identified in relative
- Fact sheet addressing frequently asked questions
regarding cancer risk, costs of genetic testing, and
insurance issues regarding genetic testing
- Contact information for genetic counselors specific
to each eligible relative based on their geographic
location. The National Society of Genetic Counselors
website (nsgc.org) was used both as a reference and
to identify genetic counselors near each of the eligi-
ble relatives.
- Support websites and brochures [25,26]
In addition to print versions of these resources, we pro-
vided each BRCA carrier with a personalized CD contain-
ing electronic versions of each resource included in the
binder. Each BRCA carrier was counseled to use print and
electronic ShaRIT resources to assist with family commu-
nication and to help answer common questions from rela-
tives. They were encouraged to disseminate these
resources to relatives, and to contact their genetic counse-
lor for assistance and support throughout this process.
These personalized and standardized binders were
developed in coordination with the physicians and
genetic counselors at the UCSF Cancer Risk Program.
These binders were used to guide and standardize the
genetic counseling process, particularly as it relates to
discussing family communication of BRCA results as
well as BRCA testing of relatives.
Survey instrument
We developed and pilot tested a semi-structured inter-
viewer-administered survey, which lasted 15-30 minutes,
depending on the number of relatives in each family. To
allow time for sharing BRCA results with relatives, we
waited at least 2 months after BRCA positive results dis-
closure before contacting the BRCA carrier (range 2-10
months post disclosure). To confirm family history and
structure, we reviewed each participant’s pedigree on file
with the Cancer Risk Program before administering the
phone survey. In addition to demographic data, the four
content domains of the survey were:
1. Pedigree knowledge.
2. Family communication, sharing results, family
testing.
3. Satisfaction with decision to BRCA test.
4. Acceptability of intervention.
Feasibility evaluation
In addition to assessing acceptability of ShaRIT from the
participant’s perspective, we also assessed its feasibility
from the genetic counselor’s perspective. We surveyed
all cancer risk genetic counselors within the UCSF Can-
cer Risk Program using an electronic survey conducted
in November 2010.
Measurements
Pedigree knowledge
Our knowledge construct consisted of six questions on
the degree of relationship and heritability probabilities
of the BRCA mutation for first-degree and second-
degree relatives. We asked participants the following
questions:
1) How would you define a first-degree relative?
2) Can you give me an example of one of your first-
degree relatives?
3) What is the chance that a first-degree relative
shares your BRCA mutation?
4) How would you define a second-degree relative?
5) Can you give me an example of one of your sec-
ond-degree relatives?
6) What is the chance that a second-degree relative
shares your BRCA mutation?
Family communication, sharing results, and family testing
T h es u r v e yq u e r i e dp a r t i c i p a n t s ’ reports of their fre-
quency of communication with each eligible relative
Table 1 Resources provided to participants during results visit with genetic counselors
Items Control ShaRIT
Personalized Medical Report Mailed after results visit X
Family Pedigree XX
BRCA mutation report from Myriad Genetics XX
Personalized Recommendations for Cancer Surveillance and Prevention X
Information for Family Members: X
*Letter to family member notifying him/her of BRCA mutation identified in relative Available to patient after results
visit if requested
X
*FAQ for family members addressing cancer risk, cost of testing, insurance issues X
*Contact information for genetic counselor(s) nearest to eligible family members X
General Information and Resources (Support group brochures, contact information for
therapists with expertise in HBOC, general information on HBOC)
XX
Files on CD-ROM X
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week, once a month, 1-6 times per year, once a year,
and less than once a year), whether or not they shared
their test results with each eligible relative, and whether
or not, to their knowledge, each relative had pursued
genetic testing for the known family mutation. If partici-
pants had shared their test results, we asked them how
they disclosed the results, and whether they informed
the relative directly of their results or if someone else
had. If participants reported that their relative had pur-
sued BRCA testing, we asked them if their relative had
tested before them and how long ago they BRCA tested.
Satisfaction with the decision to BRCA test
We used a validated seven-question satisfaction with
decision scale [27] to query the decision to undergo
genetic testing for cancer risk. These questions assessed
the following: feeling adequately informed about
options, making a decision consistent with personal
values, having adequate input in the decision, and hav-
ing a positive effect on the participant’s family. All ques-
tions used the same five-point Likert scale for responses.
Acceptability of intervention
We asked participants in the control group if they saved
copies of their BRCA mutation report and personalized
medical report. If they responded “yes” to either of
these, they were asked if they shared these materials
with their relatives. They were also asked if any relatives
asked questions that they weren’t comfortable answer-
ing. To assess for acceptability of ShaRIT components
not previously distributed to BRCA carriers, we asked
control group participants if they thought a single-page
Frequently Asked Questions sheet, a list of relatives that
should consider BRCA testing, or receiving information
from their genetic counselor in an electronic format
would have been helpful.
We asked participants in the ShaRIT group if they
remembered receiving a binder at their results visit, and
if so, whether they saved it. We asked if they shared any
of the information in the binder with their relatives, and
which materials they used and found most helpful.
ShaRIT participants were also asked if any relatives
asked questions that they weren’t comfortable answer-
ing. We queried ShaRIT participants about aspects of
the binder that were not helpful and about additional
materials that should be included in future binders.
Finally, we asked about the overall utility of ShaRIT,
including the binder and the accompanying genetic
counseling sessions.
The feasibility survey conducted among the four
genetic counselors at the Cancer Risk Program who
counsel patients at risk for HBOC asked the following
questions:
1 )H o wl o n gd o e si tt a k et op r e p a r eaS h a R I Tb i n d e r
for each patient?
2) Have you encountered any difficulties in preparing
for ShaRIT?
3) Has ShaRIT increased/decreased your workload and
time spent with patients? If so, how?
4) What is your overall satisfaction with ShaRIT, the
final genetic counseling session, your communication
with your patient, and the knowledge your patient
gained regarding his/her test result?
5) List three things you like most about ShaRIT.
6) List three things you like least about ShaRIT.
Study outcomes
The primary outcomes of this pilot study were the feasi-
bility and acceptability of the ShaRIT intervention.
These outcomes were assessed by interviewing genetic
counselors and participants, respectively, using the ques-
tions described above in the Measurements section.
The secondary, quantitative outcomes of this study
were 1) participants’ report of sharing BRCA results
with eligible family members and 2) participants’ report
of relatives receiving BRCA testing. Although it is possi-
ble that reports of BRCA testing could differ if partici-
pants or their relatives are queried, our consent process
did not allow us to directly contact relatives. This
approach has been followed in prior studies of our study
outcomes [11,21].
Data analysis
Descriptive and comparative statistics were used to
characterize participants in terms of demographics, self-
reported annual income, pedigree knowledge, satisfac-
tion with decision to BRCA test, and mean number of
relatives. We examined potential differences between
control and intervention populations using t tests and
c2 tests, where applicable.
For analyses regarding the feasibility and acceptability
of ShaRIT, we used quantitative and qualitative methods
to record responses from the participant and genetic
counselor surveys. We tallied these responses and also
analyzed them for common themes.
For analyses regarding the communication of BRCA
results to relatives, we classified responses by first-
degree relatives, second-degree relatives, and cousins.
We then compared sharing rates by these classifications.
We followed a similar protocol for analyses of family
testing. To measure reports of sharing test results with
relatives and of relatives receiving genetic testing, we
used a two-step process. First, we calculated the propor-
tion of eligible relatives for each outcome by participant.
Then, we measured frequencies of sharing and testing
for each type of relative.
We analyzed the following characteristics that have
been shown in prior studies to be associated with shar-
ing and family testing: gender, type of relative, and
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measure, pedigree knowledge (as described above), for
its association with sharing and family testing. Data ana-
lysis was done with Stata 12.0 statistical software
(STATA Corp).
Results
Study population
During the eligibility period for this time-series analysis,
we identified 37 women who met our inclusion criteria.
Twenty-five of these were informed of their BRCA posi-
tive results between August 2009 and January 2010
(time period for the control group). Twelve were
informed of their BRCA positive results between Febru-
ary 2010 and June 2010 (time period for the ShaRIT
group). Eleven of the twenty-five women eligible for the
control group participated in the phone survey (44%).
Two of the women interviewed from the control group
were cousins. Survey responses from the second woman
interviewed from that family were excluded from ana-
lyses, to ensure that outcomes from this family were not
counted twice. Nine of the twelve women eligible for
the ShaRIT group participated in the phone survey
(75%).
Study participants in the control and ShaRIT groups
did not differ in their race, ethnicity, Ashkenazi Jewish
ancestry, annual reported income, or satisfaction with
decision to BRCA test (Table 2). Although not statisti-
cally significant, the control group was slightly older and
had a wider range of ages. Women in the ShaRIT group
had slightly higher pedigree knowledge scores, although
differences in scores between groups were not statisti-
cally significant.
Acceptability and feasibility of ShaRIT
Participant perspectives
In the control group, 70% of participants reported that
additional information and resources regarding sharing
results and family testing would have been useful. One
control participant reported, “a Frequently Asked Ques-
tions (FAQ) sheet would have been helpful because
there were a lot of questions I couldn’ta n s w e r ” from
her relatives. Another suggested electronic versions of
family letters and resources, as “it is much easier to talk
about over email than over the phone.” She also said
she would have liked additional information regarding
the “implications of (a) positive result” and “statistics on
developing breast or ovarian cancer”. 40% of the control
group mentioned that electronic resources would have
been useful, and 20% of the control group would have
liked additional information on how a positive test result
affects family planning for themselves and their relatives.
One control group participant requested contact
information of genetic counselors in other areas for her
relatives.
In the ShaRIT group, 100% of participants reported
that they saved their ShaRIT binder and they felt it was
a useful resource. 44% reported that they gave or plan
to give ShaRIT resources to their relatives, and 22%
reported that additional information (more resources or
handouts) would have been helpful to include in
ShaRIT. For example, one ShaRIT participant would
have liked a Spanish version of the FAQ sheet for her
Spanish-speaking relatives. Only one ShaRIT participant
felt the binder itself wasn’t necessary. Three ShaRIT par-
ticipants (33%) preferred the electronic CD-ROM ver-
sion to the paper materials.
ShaRIT participants were asked open-ended questions
about particularly useful components of the binder. One
felt the binder was a “good means to give a package of
information with options, results, recommended doctors,
referrals, and the family tree” to relatives. Another
reported, “I’m a visual person, and until I sit down and
read it I don’t get it reinforced. It was nice to have it
down in writing.” Yet another said that the mutation
report was useful and that “it was good to have written
information to give to my cousin about screening.”
Genetic counselor perspectives
Genetic counselors at the UCSF Cancer Risk Program,
who aided in the development of ShaRIT, have found
the binder, accompanied by genetic counseling, to be
both feasible and useful in clinically guiding high-risk
patients through understanding the implications of
Table 2 Characteristics of BRCA positive participants (n =
19)
Control ShaRIT p*
n=1 0 n=9
Age
Mean 49 (± 8) 40 (± 6) 0.06
Range 26-63 33-49
Race/Ethnicity 0.47
Caucasian 7 (70%) 7 (78%)
Hispanic 2 (20%) 0 (0)
African American 0 (0) 1 (11%)
South Asian/Indian 0 (0) 1 (11%)
Asian/Pacific Islander 1 (10%) 0 (0)
Ashkenazi Jewish 2 (20%) 1 (11%) 1.00
Annual Reported Income
a 1.00
≤ $100,000 2 (22%) 2 (22%)
$100,001-$500,000 7 (78%) 7 (78%)
Pedigree Knowledge (scale 0-6) 4.9 (± 1.4) 5.3 (± 1.3) 0.49
Average Score 4.3 (± 0.16) 4.5 (± 0.11) 0.23
Satisfaction with Decision (scale 0-5)
* Fisher’s exact test used for cell sizes ≤ 2 or percentages less than 20%
a. One participant in the control group declined to report her annual income
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counselors queried reported that ShaRIT provides struc-
ture to their sessions. These counselors also all reported
that ShaRIT allows results disclosure sessions to have a
dual focus–on implications for the individual and for
the family. One counselor said, “it (compiling ShaRIT
materials) does increase my workload by about 30 min-
utes per patient, but it is worth it because I feel more
organized and the patients seem to really appreciate the
resources.” When asked about her overall satisfaction
with her communication with patients, the same coun-
selor said, “It allows patients to be more focused on
their feelings because they know that all the information
they need is right in front of them.”
Sharing and testing in relatives
In total, there were 207 relatives eligible for sharing and
198 of those were considered eligible for testing by our
criteria outlined above. Of the relatives eligible for shar-
ing, 59 were first-degree relatives (37 in the control
group, 22 in the intervention group), 57 were second-
degree relatives (33 in the control group, 24 in the inter-
vention group), and 91 were cousins (64 in the control
group, 27 in the intervention group). Of the relatives eli-
gible for testing, 54 were first-degree relatives (36 in the
control group, 18 in the intervention group), 53 were
second-degree relatives (33 in the control group, 20 in
the intervention group), and 91 were cousins (64 in the
control group, 27 in the intervention group). The med-
ian number and range of first-degree relatives, second-
degree relatives, and cousins in both groups are shown
in Table 3 as well as the proportion of relatives told and
tested by participant.
Sharing rates for all first-degree relatives were over
95% overall; only two participants, one each in the con-
trol and ShaRIT groups reported not sharing their
results with all of their first-degree relatives. Only 38%
of control group participants told all of their second-
degree relatives about their results, while 75% did so in
the ShaRIT group. Sharing rates were similar for cousins
across both groups.
Testing rates in eligible relatives were generally lower
than sharing rates and displayed a similar decrease from
first-degree relatives to second-degree relatives by parti-
cipant group, except for second-degree relatives of con-
trol group participants. 67% of control group
participants reported that all their eligible second-degree
relatives tested, with only 14% of participants in the
ShaRIT group reporting that all of their second-degree
relatives had tested. No participants reported that all of
their eligible cousins had tested. Among those partici-
pants aware of testing outcomes in their cousins, testing
rates ranged from 0-71% in the control group and 0-
50% in the ShaRIT group.
Table 3 shows the median number and range of first-
degree relatives, second-degree relatives, and cousins for
participants in the control and ShaRIT groups. For each
participant, we calculated the percentage of each type of
relative told about the participant’s BRCA results. We ana-
lyzed relative uptake of BRCA testing in a similar manner.
We also examined patterns in sharing and testing
based on relative characteristics for first-degree relatives,
second-degree relatives, and cousins of participants.
Female relatives were more often told about the partici-
pant’s BRCA results, and were also more likely to
undergo BRCA testing (Figure 3). Rates of sharing for
first-degree relatives are very high, particularly when
compared with sharing rates for all second-degree rela-
tives except nieces. Sharinga n dt e s t i n go u t c o m e sf o r
twelve different types of relatives are displayed in Figure
3, which was analyzed independent of intervention,
using the combined control and ShaRIT groups.
Figure 4 shows the relationship between sharing and
testing and frequency of communication between study
participants (control and ShaRIT groups combined) and
their relatives. In general, more frequent communication
between participants and relatives was associated with
more frequent sharing and testing.
Sharing and testing outcomes by participant based on
pedigree knowledge score are shown in Figure 5. This
demonstrates a trend toward increased communication
with increasing levels of pedigree knowledge, but not
necessarily increased testing with increasing pedigree score.
Discussion
This pilot study of a personalized educational interven-
tion, the Sharing Risk Information Tool (ShaRIT),
Table 3 Characteristics and study outcomes of relatives
by participant
a
Control
(n = 10)
ShaRIT
(n = 9)
p
Median Number (Range) of:
First-Degree Relatives 3.0 (0-8) 2.0 (1-7) N/A
Second-Degree Relatives 2.5 (0-9) 2.0 (1-6)
Cousins 3.5 (0-27) 2.0 (1-11)
Shared Results with all Eligible Relatives
First-Degree Relatives 88% 90% 1.00
Second-Degree Relatives 38% 75% 0.32
Cousins 40% 63% 0.86
All Eligible Relatives Tested
First-Degree Relatives 25% 20% 1.00
Second-Degree Relatives 67% 14% 0.10
Cousins 0% 0% N/A
a. Proportion of relatives with whom results shared or who tested by
participant. If participant did not know whether or not BRCA results were
shared with that relative, or whether or not that relative tested, then fields
were left blank. Fisher’s exact test was used to compare sharing and testing
outcomes between groups
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care for both patients and genetic counselors. We also
used this pilot study to successfully test a phone survey
instrument that measures rates of sharing results and
testing relatives in families with a known BRCA muta-
tion. Our results provide preliminary data that can be
used to design larger studies and trials of interventions
to improve risk communication in families with heredi-
tary cancer syndromes. Additionally, our data confirms
prior studies of characteristics associated with increased
sharing and BRCA testing rates. Finally, we identified a
new predictor associated in this pilot study with
increased family communication: pedigree knowledge.
We believe the SharIT binder and accompanying
genetic counseling sessions are feasible and acceptable
ways to promote communication of BRCA test results
to at-risk family members, as assessed by feedback
received from both study participants and genetic coun-
selors. The genetic counselors at the UCSF Cancer Risk
Program felt that the additional 30 minutes required to
compile the binder was worth their time as it better
structured their counseling sessions with each patient
and provided their patients with a resource to utilize
after the final counseling session. All participants in the
ShaRIT group were receptive to the binder as a refer-
ence to which they could refer at a later date and as a
resource they could offer to their family members.
Our secondary aims to assess predictors of sharing
and testing will better inform larger, future studies. Our
results are similar to prior studies, which have demon-
strated sharing rates of 59% to 86% in first- and second-
degree relatives [9-12]. Our testing rates are also within
the range of prior studies (36% of all eligible first- and
second-degree relatives in one study; 57% in another)
[9,15]. As with prior research, we found that first-degree
relationships and female gender were associated with
increased sharing and testing outcomes, particularly in
the younger generations. In this pilot study, 100% of eli-
gible daughters and nieces were reported to have
received BRCA testing for the known family mutation.
Although cousins are third-degree relatives, we felt
that it was important to assess their sharing and testing
outcomes as well. In this pilot study, the number of at-
risk cousins ranged from 0-27 per family. No families in
either the ShaRIT or control group tested all eligible
cousins (Table 3). Female cousins were more likely to
BRCA test than their male counterparts (Figure 3). We
consider this data on cousins a strength of our study,
and a model for both counseling practice and future
studies in this area.
We measured pedigree knowledge, the novel predictor
of increased sharing rates that we identified, with six
questions. Participants with higher pedigree knowledge
reported higher rates of sharing BRCA results with rela-
tives, but not necessarily higher rates of family genetic
testing. This relationship implies that patients with
greater knowledge may feel more comfortable commu-
nicating their BRCA results with relatives. With regard
Figure 3 Sharing and testing in eligible relatives based on
relative gender and relationship to participant.
Figure 4 Sharing and testing in eligible relatives based on
frequency of communication with participant.
Figure 5 Sharing and testing outcomes in all relatives based
on participant’s pedigree knowledge score. Score was calculated
as the number of correct responses out of six total questions. None
of the participants scored 0, 1, or 4 on the pedigree knowledge
questions.
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they choose to share their results with, but do not con-
trol their relative’s decision to test for the known family
mutation. Pedigree knowledge could prove to be an
important variable that may be modified with targeted
counseling and education. Further studies could exam-
ine whether increases in pedigree knowledge may result
in improved sharing and family testing in larger popula-
tions of families with hereditary cancer syndromes.
This study is strengthened by the consideration of
individual family structure–each participant’sp e d i g r e e
was studied before she was surveyed, and each eligible
relative was individually assessed for sharing and testing
outcomes. It is also strengthened by qualitative feedback
from participants and from genetic counselors, which
indicate both the feasibility and acceptability of ShaRIT.
We recognize several limitations of our study, which
we have carefully considered in our interpretation of
results. This was a pilot study of 19 families (10 control
and 9 intervention), which made it difficult to suffi-
ciently assess the independent predictive value of
ShaRIT for family communication and testing outcomes.
From these 19 families, however, we collected data on
approximately 200 relatives eligible for sharing and
family testing. Interestingly, participants in the control
group had more second-degree relatives and cousins
than the participants in the ShaRIT group, which may
have further affected our ability to detect differences
between the study groups. This pilot study was not
powered to detect differences in sharing and family test-
ing between the control and ShaRIT groups; rather, it
served the purpose of demonstrating the feasibility and
acceptability of ShaRIT. Our results provide estimates of
the time, resources, and effect sizes needed to design a
larger multi-site trial of ShaRIT.
This study design identified control and intervention
groups based on the time of their genetic test result dis-
closure visit. Therefore, families in the control group
had more time (up to eight additional months) to share
results and to test relatives for the known family muta-
tion. Prior studies have shown that sharing often occurs
within a few weeks after genetic test result disclosure
[28]. Testing of relatives, on the other hand, typically
involves longer periods of time [14]. Because of the time
series analysis of this study, it is possible that testing
rates in the ShaRIT group would be higher if their fol-
low-up time had been similar to that of the control
group. We expect that longer follow-up of the ShaRIT
group would identify higher testing rates for relatives.
Future studies of ShaRIT and other similar interventions
should consider designs to ensure similar follow-up
times, including randomized controlled trials.
Because we recruited participants from a single site
tertiary cancer center at a university hospital, it is
unclear whether our results would generalize to other
populations. The ethnic diversity of our population is
r e f l e c t e di nt h a t2 6 %o fp a r t icipants in this study were
non-Caucasian. We plan to develop a Spanish version of
ShaRIT and to test it in Hispanic populations through-
out the United States. We are hopeful that we can per-
form future large multi-site studies of ShaRIT in diverse
populations.
Conclusions
To our knowledge, this pilot study is the first to exam-
ine the feasibility of a clinically- delivered, personalized
educational intervention to improve communication and
uptake of genetic testing in families with Hereditary
Breast and Ovarian Cancer Syndrome. Our quantitative
and qualitative results demonstrate the feasibility and
acceptability of the Sharing Risk Information Tool
(ShaRIT) for patients and for genetic counselors. Future
research in this field should examine the impact of
ShaRIT and other similar interventions in larger and
more diverse populations in the setting of a multi-site
randomized controlled trial.
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